VIR - NASDAQ
Vir Biotechnology, Inc.
$8.77
+0.34%Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotVir Biotechnology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Vir Biotechnology, Inc. Income Statement
VIR • NASDAQ
| Vir Biotechnology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
68.6M | 74.2M | 86.2M | 1.6B | 1.1B | 67.2M | 711K | 868K | 149K | |
GROSS PROFIT | |||||||||
(11.7M) | (478.6M) | (572.8M) | (621M) | (513.9M) | (0.0) | (0.0) | (100.2M) | (62.5M) | |
56.9M | -404.4M | -486.6M | 994.8M | 581.5M | 67.2M | 711K | -99.4M | -62.4M | |
OPERATING INCOME | |||||||||
(524.9M) | (182.7M) | (197.7M) | (161.8M) | (160.8M) | (364.2M) | (178.7M) | (119.6M) | (81.6M) | |
(92.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (70.9M) | (37.6M) | (29.1M) | (21.7M) | |
(432.8M) | (506.5M) | (579.7M) | (474.6M) | (448M) | (302.4M) | (148.5M) | (100.2M) | (62.5M) | |
-468M | -587.2M | -684.3M | 833.1M | 420.8M | -297M | -178M | -118.7M | -81.5M | |
PRE-TAX INCOME | |||||||||
40.2M | 71.8M | 87M | 28.1M | 439K | 2.8M | 8.5M | 2.5M | 638K | |
(0.0) | -323.8M | -382.1M | -312.9M | -287.2M | -9.1M | -7.4M | -212K | (83K) | |
30.3M | 64.1M | 56.1M | -78.8M | 129.1M | -1.6M | 3.5M | 2.3M | 721K | |
-437.8M | -523.1M | -628.2M | 754.3M | 549.8M | -298.6M | -174.5M | -116.4M | -80.8M | |
NET INCOME | |||||||||
(217K) | -1.1M | -13.1M | (238.4M) | (21.2M) | (54K) | (154K) | -480K | -10.9M | |
-438M | -522M | -615.1M | 515.8M | 528.6M | -298.7M | -174.7M | -115.9M | -69.9M |
SEC Filings
VIR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 25, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your VIR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.